Last reviewed · How we verify
Phase IIb formulation
At a glance
| Generic name | Phase IIb formulation |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older (PHASE2)
- Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) (PHASE3)
- A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (PHASE2)
- Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia (PHASE1, PHASE2)
- HRIPT Study to Evaluate the Irritation and Allergenic Potential of Medical-grade Norway Spruce (Picea Abies) Resin Salve (Abilar) (NA)
- Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (PHASE2)
- A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis (PHASE2)
- Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase IIb formulation CI brief — competitive landscape report
- Phase IIb formulation updates RSS · CI watch RSS
- AstraZeneca portfolio CI